Versartis (VSAR) Set to Announce Quarterly Earnings on Wednesday

Versartis (NASDAQ:VSAR) is scheduled to be announcing its earnings results after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of ($0.97) per share for the quarter.

Shares of Versartis (NASDAQ:VSAR) opened at $1.73 on Wednesday. Versartis has a 52-week low of $1.60 and a 52-week high of $24.00. The company has a market cap of $60.88, a PE ratio of -0.44 and a beta of 2.11. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.52 and a current ratio of 1.52.

Several equities research analysts have recently commented on VSAR shares. Cantor Fitzgerald set a $14.00 price target on shares of Versartis and gave the company a “buy” rating in a research report on Friday, October 27th. Zacks Investment Research lowered shares of Versartis from a “hold” rating to a “sell” rating in a research report on Sunday, January 21st. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $5.63.

In related news, insider Jay Shepard sold 14,446 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $1.80, for a total value of $26,002.80. Following the completion of the sale, the insider now directly owns 602,298 shares of the company’s stock, valued at approximately $1,084,136.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Srinivas Akkaraju bought 513,872 shares of Versartis stock in a transaction that occurred on Monday, December 4th. The stock was purchased at an average cost of $2.21 per share, with a total value of $1,135,657.12. Following the completion of the acquisition, the director now directly owns 14,955 shares in the company, valued at approximately $33,050.55. The disclosure for this purchase can be found here. Insiders have sold a total of 21,400 shares of company stock valued at $38,520 in the last ninety days. Insiders own 10.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Earnings History for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with's FREE daily email newsletter.

Leave a Reply